Mucosal vaccines for HPV

References

• Administration US FDA. Secondary food additives permitted in food for human consumption; food additives permitted in feed and drinking water of animals; aminoglycoside 3'-phosphotrans- ferase II; Final Rule Federal Register 1994;59: 26700–11.
   Google Scholar
• Ashkar AA, Rosenthal KL. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 2003;77:10168–71.
   PubMed Web of Science ®Google Scholar
• Balmelli C, Demotz S, Acha-Orbea H, De Grandi P, Nardelli- Haefliger D. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. J Virol 2002;76:12596–602.
   PubMed Web of Science ®Google Scholar
• Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli- Haefliger D. Nasal immunization of mice with human papillo- mavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998;72:8220–9.
   PubMed Web of Science ®Google Scholar
• Baud D, Fraillery D, Bobst M, Zosso N, Ponci F, De Grandi P et al. Salmonella live vaccine strains against human papillomavirus type 16 pre-clinical trials. 2005; Submitted.
   Google Scholar
• Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles using a codon-opti- mized version of L1. J Virol 2004;78:12901–9.
   PubMed Web of Science ®Google Scholar
• Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microb 2003;38:13–22.
   PubMed Web of Science ®Google Scholar
• Belay T, Eko FO, Ananaba GA, Bowers S, Moore T, Lyn D et al. Chemokine and chemokine receptor dynamics during genital chlamydial infection. Infect Immun 2002;70:844–50.
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Ahlers JD, Brandwein BY, Earl P, Kelsall BL, Moss B et al. The importance of local mucosal HIV-specific CD8+ cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest 1998;102:2072–81.
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004;113:998–1007.
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Hel Z, Kelsall BL, Kuznetsov V, Ahlers JD, Woodward R et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques Nat Med 2001,7:1320–6.
   Google Scholar
• Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74:185–5.
   PubMed Web of Science ®Google Scholar
• Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, Alcocer- Gonzalez JM, Tamez-Guerra RS, Montes de Oca-Luna R et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004;53:427–33.
   PubMed Web of Science ®Google Scholar
• Berry LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hans-bro PM et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 2004;72:1019–28.
   PubMed Web of Science ®Google Scholar
• Bertley FMN, Kozlowski PA, Wang S-W, Chapelle J, Patel J, Sonuyi O et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA- modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 2004;172:3745–57.
   PubMed Web of Science ®Google Scholar
• Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Muller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003;77:9211–20.
   PubMed Web of Science ®Google Scholar
• Black A, Rohan LC, Cost M, Watkins SC, Draviam R, Alber S et al. Vaginal mucosa serves as an inductive site for tolerance. J Immunol 2000;165:5077–83.
   PubMed Web of Science ®Google Scholar
• Corona Gutierrez CM, Tinoco A, Navarro T, Lopez Contreras M, Risco Cortes R, Calzado P et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN1, CIN2 and CIN3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004;15:421–31.
   PubMed Web of Science ®Google Scholar
• Curtiss R, Hassan JO, Herr J, Kelly SM, Levine M, Mahairas GG et al. Nonrecombinant and recombinant avirulent Salmonella vaccines. In: Talwar GP. (ed) Recombinant and Synthetic Vaccines. New Delhi: Narosa, 1994.
   Google Scholar
• Da Silva D, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP et al. Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol 2001;186:169–82.
   PubMed Web of Science ®Google Scholar
• Dumais N, Patrick A, Moss RB, Davis HL, Rosenthal KL. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis 2002;86:1098–105.
   Web of Science ®Google Scholar
• Ellen JM, Lammel CJ, Shafer M-A, Teitle E, Schachter J, Stephens RS. Cervical secretory immunoglobulin A in adolescent girls. J Adolescent Health 1999;25:150–4.
   PubMed Web of Science ®Google Scholar
• Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 2002;14:666–72.
   PubMed Web of Science ®Google Scholar
• Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, Drijfhout JW, Melief CJ et al. Vaccination with cytotoxic T lymphocyte epi- tope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242–9.
   PubMed Web of Science ®Google Scholar
• Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998;177:1155–61.
   PubMed Web of Science ®Google Scholar
• Garland SM. Imiquimod. Curr Opin Infect Dis 2003;16:85–9.
   PubMed Web of Science ®Google Scholar
• Gerber S, Lane C, Brown D, Lord E, DiLorenzo M, Clements JD et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coliheat-labile enterotoxin mutant R192G or CpG DNA. J Virol2001;75:4752–60.
   PubMed Web of Science ®Google Scholar
• Germanier R, Fürer E. Isolation and characterization of galE mutant Ty 21a of Salmonella typhi. A candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975;131:553–8.
   PubMed Web of Science ®Google Scholar
• Gey A, Kumri P, Sambandam A, Lecuru F, Cassard L, Badoual C et al. Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratu- moral type 1 (IFN-γ) and type 2 (IL-4) cytokine mRNA expression. Eur J Cancer 2003;39:595–603.
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Pérez-Jiménez E, Nájera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime- modified vaccinia virus Ankara boost immunization schedule. J Immunol 2004;172:6209–20.
   PubMed Web of Science ®Google Scholar
• Giannini SL, Al-Saleh W, Piron H, Jacobs N, Doyen J, Boniver J et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 1998;113:183–9.
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hubert P, Doyen J, Boniver J, Delvenne P. Influence of the mucosal epithelium microenvironment on Langerhans' cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002;97:654–9.
   PubMed Web of Science ®Google Scholar
• Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL et al. The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. Vaccine 2000;19:1008–12.
   PubMed Web of Science ®Google Scholar
• Gupta S, Janani R, Bin Q, Luciw P, Greer CE, Perri S et al. Characterization of human immunodeficiency virus gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol 2005;79:7135–45.
   PubMed Web of Science ®Google Scholar
• Hamann A, Andrew DP, Jablonski WD, Holzmann B, Butcher EC. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994;152: 3282–93.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757–65.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003;21:S89–95.
   PubMed Web of Science ®Google Scholar
• Jabbar IA, Fernando GJP, Saunders N, Aldovini A, Young R, Malcolm K et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000;18:2444–53.
   PubMed Web of Science ®Google Scholar
• Johansen F-E, Brandtzaeg P. Transcriptional regulation of the mucosal IgA system. Trends Immunol 2004;25:150–7.
   PubMed Web of Science ®Google Scholar
• Johansson M, Lycke NY. A unique population of extrathymically derived aαTCR+CD4-CD8- T cells with regulatory functions dominates the mouse female genital tract. J Immunol 2003;170:1659–66.
   PubMed Web of Science ®Google Scholar
• Kelly KA, Rank RG. Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun 1997;65:5198–208.
   PubMed Web of Science ®Google Scholar
• Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, Chea S et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIV SF162P3. Vaccine 2005; 23:5009–21.
   PubMed Web of Science ®Google Scholar
• Klavinskis LS, Bergmeier LA, Gao LQ, Mitchell E, Ward RG, Layton G et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996;157:2521–7.
   PubMed Web of Science ®Google Scholar
• Kleine-Lowinski K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile J, Münger K et al. Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 2003;107:407–15.
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault DA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645–51.
   PubMed Web of Science ®Google Scholar
• Kutteh WH. Mucosal Immunity in the Human Female Reproductive Tract, 2nd edn. San Diego, CA: Academic Press, 1999.
   Google Scholar
• Levine MM, Woodrow GC, Kaper JB, Cobon GS. Attenuated Salmonella as a live vector for expression of foreign antigens. New York: Dekker, 1997.
   Google Scholar
• Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer 2002;102:629–37.
   PubMed Web of Science ®Google Scholar
• Lin KY, Guarnieri FG, Staveleyocarroll KF, Levitsky HI, August JT, Pardoll DM et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21–6.
   PubMed Web of Science ®Google Scholar
• Liu MA, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004;101(Suppl2):14567–71.
   PubMed Web of Science ®Google Scholar
• Liu XS, Abdul JI, Qi YM, Frazer IH, Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998;252:39–45.
   PubMed Web of Science ®Google Scholar
• Musey L, Ding Y, Cao J, Lee J, Galloway C, Yuen A et al. Ontogeny and specificities of mucosal and blood human immunodeficiency virus type 1-specific CD8+ cytotoxic T lymphocytes. J Virol 2003;77:291–300.
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR et al. Immune responses induced by lower airway mucosal immunization with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005;23:3634–41
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol 1999;74:9609–13.
   Google Scholar
• Nardelli-Haefliger D, Wirthner D, Schiller J, Lowy DR, Hildesheim A, Ponci F et al. Specific antibody levels at the cervix during the menstrual-cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003;95:1128–37.
   PubMed Web of Science ®Google Scholar
• Ogra P, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14:430–45.
   PubMed Web of Science ®Google Scholar
• Ohlschlager P, Osen W, Dell K. Human papillomavirus type 16 L1 capsomeres induces L1-specific cytotoxic T lymphocytes and tumour regression in C57BL/6 mice. J Virol 2003;77:4635–45.
   PubMed Web of Science ®Google Scholar
• Park JS, Oh YK, Kang MJ, Kim CK. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J Med Virol 2003;70:633–41.
   PubMed Web of Science ®Google Scholar
• Parr MB, Parr EL. Interferon-γ up-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2. Immunology 2000;99:540–5.
   PubMed Web of Science ®Google Scholar
• Phalipon A, Corthésy B. Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins. Trends Immunol 2003;24:55–8.
   PubMed Web of Science ®Google Scholar
• Ramirez JC, Finke D, Esteban M, Kraehenbuhl JP, Acha-Orbea H. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 2003;148:827–39.
   PubMed Web of Science ®Google Scholar
• Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like-particles (VLPs) or HPV16 VLPs purified form insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 2001;279:354–60.
   PubMed Web of Science ®Google Scholar
• Roden R, Ling M, Wu T-C. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004;35:971–82.
   PubMed Web of Science ®Google Scholar
• Rose JR, Williams MB, Rott LS, Butcher EC, Greenberg HB. Expression of the mucosal homing receptor alpha 4 beta 7 correlates with the ability of CD8+ memory T cells to clear rotavirus infection. J Virol 1998;72:726–30.
   PubMed Web of Science ®Google Scholar
• Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL. Oral vaccination of mice with human papillomavirus viruslike particles induces systemic virus-neutralizing antibodies. Vaccine 1999;17:2129–35.
   PubMed Web of Science ®Google Scholar
• Sasagawa T, Tani M, Basha W, Rose CR, Tohda H, Giga-Hama Y et al. A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res 2005;110:81–90.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2:343–7.
   PubMed Web of Science ®Google Scholar
• Schödel F. Prospects for oral vaccination using recombinant bacteria expressing viral epitopes. Adv Vir Res 1992;41:409–46.
   PubMed Web of Science ®Google Scholar
• Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004;16:485–91.
   PubMed Web of Science ®Google Scholar
• Shi W, Liu J, Huang Y, Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lym- phocyte responses. J Virol 2001;75:10139–48.
   PubMed Web of Science ®Google Scholar
• Stern PL Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005; 32Suppl:S72–81.
   Google Scholar
• Stevceva L, Moniuszko M, Alvarez X, Lackner AA, Franchini G. Functional simian immunodeficiency virus gag-specific CD8+ intraepithelial lymphocytes in the mucosa of SIV mac 251- or simian-human immunodeficiency virus KU2-infected macaques. Virology 2004;319:190–200.
   PubMed Web of Science ®Google Scholar
• Van der Burg SH, De Jong JH, Welters MJP, Offringa R, Melief CJ. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res 2002;89:275–84.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. Prophylactic quadrivalent human papillomavirus (types 6, 11,16 and 18) L1 virus-like particle vaccine in young women:a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–8.
   PubMed Web of Science ®Google Scholar
• Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL et al. Oral immunogenicity of human papillo- mavirus-like particles expressed in potato. J Virol 2003;77:8702–11.
   PubMed Web of Science ®Google Scholar